Ziopharm Oncology (ZIOP +1.8%) trades higher after intitiating Phase 2 clinical studies of...
Ziopharm Oncology (ZIOP +1.8%) trades higher after intitiating Phase 2 clinical studies of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer.
From other sites
at Nasdaq.com (Wed, 12:09PM)
at CNBC.com (Jan 16, 2015)
at Benzinga.com (Jan 15, 2015)
at MarketWatch.com (Jan 14, 2015)
at Nasdaq.com (Jan 14, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs